Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Moderate Buy” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company.

Several research analysts have recently commented on the company. Zacks Research lowered Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 24th. DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY stock opened at $11.24 on Friday. Bayer Aktiengesellschaft has a twelve month low of $6.20 and a twelve month high of $14.85. The stock has a market capitalization of $44.17 billion, a price-to-earnings ratio of -10.13 and a beta of 0.62. The stock has a fifty day simple moving average of $11.40 and a two-hundred day simple moving average of $10.85. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.2 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.